Seer Inc Ordinary Shares - Class A SEER
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Seer to Report Third Quarter 2026 Financial Results on November 10, 2026
-
Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
-
Seer Announces CFO Transition
-
Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale
-
Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.’s Board of Directors
-
Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
-
Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook
-
Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference
Trading Information
- Previous Close Price
- $1.93
- Day Range
- $1.89–2.01
- 52-Week Range
- $1.55–2.38
- Bid/Ask
- $1.96 / $2.17
- Shares Outstanding
- 55.37M
- Market Cap
- $108.53M
- Volume/Avg
- 122,284 / 433,014
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 4.64%
Company Profile
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 124
- Website
- https://www.seer.bio
Valuation
|
Metric
|
SEER
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.48 |
Price/Sales | 7.96 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SEER
|
|---|---|
Quick Ratio | 13.87 |
Current Ratio | 14.74 |
Interest Coverage | — |
Quick Ratio
SEER
Profitability
|
Metric
|
SEER
|
|---|---|
Return on Assets (Normalized) | −20.42% |
Return on Equity (Normalized) | −23.10% |
Return on Invested Capital (Normalized) | −23.86% |
Return on Assets
SEER
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|c%sS@gR | LOCK|@HLg | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<?@<Z> | LOCK|FgyY | $84B | |||
| Moderna Inc
MRNA
| LOCK|Qf<<?S | LOCK|bb | $83B | |||
| argenx SE ADR
ARGX
| LOCK|%D?$>B! | LOCK|$^@ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|ZX#?#>$ | LOCK|%# | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Tp#@^n | LOCK|Z%^V | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>lxvbD# | LOCK|$r^wP | $29B | |||
| Incyte Corp
INCY
| LOCK|Rqs%^#X | LOCK|HzD | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|P<r@^C | LOCK|?NV | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|QR??QC | LOCK|D^T | $14B |
United States